Long-term impact of oral cladribine on humoral immunity in multiple sclerosis.

ABSTRACT:

Background

Cladribine (CLAD), an immune reconstitution therapy for active multiple sclerosis (MS), can reduce intrathecal antibody production.

Objectives

In this study, we investigated the long-term impact of oral CLAD on protective antibody levels, essential for preventing infections and immune defense.

Design

Observational long-term study including a cohort of 15 CLAD-treated MS patients.

Methods

We longitudinally studied the humoral immunity to seven common pathogens (measles, mumps, varicella-zoster virus, diphtheria and tetanus toxin, rubella, hepatitis B virus (HBV)) and absolute immunoglobulin G (IgG) levels prior to CLAD treatment (baseline, BL; 12/2017-03/2020) and after an average of 73 months (long-term) follow-up to explore the impact on pre-existin

SUBMITTER: Messner M 

PROVIDER: S-EPMC12322351 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature